P2.05. SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Samantha Low
Meta Tag
Speaker Samantha Low
Topic Metastatic NSCLC: Immunotherapy - Biomarker
performance status
Scottish Inflammatory Prognostic Score
advanced non-small cell lung cancer
prognostic tools
neutrophil count
albumin level
survival outcomes
treatment decisions
Powered By